Sunitinib is a multitargeted kinase inhibitor that has recently been approved for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumours. Raymond and colleagues summarize the discovery and development of sunitinib, and discuss key issues for the multitargeted approach in cancer treatment, such as markers of response and development of resistance.
- Sandrine Faivre
- George Demetri
- Eric Raymond
